Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids

NCT00032305 is registered in ClinicalTrials.gov with Facet Biotech as lead sponsor.

NCT NCT00032305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00032305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients With Severe Ulcerative Colitis That is Refractory to Corticosteroids
Lead sponsor
Facet Biotech
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2002
Completion date
November 30, 2005
Enrollment
20
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis